How should a 72-year-old atopic man with a persistent asthma exacerbation lasting more than one month despite intermittent budesonide (inhaled corticosteroid) / formoterol (long‑acting β2‑agonist) therapy be managed?

Management of Persistent Asthma Exacerbation in a 72-Year-Old on Intermittent Budesonide/Formoterol

This patient requires immediate transition to scheduled daily controller therapy with budesonide/formoterol (or equivalent ICS/LABA combination) rather than continuing intermittent use, plus a short course of oral corticosteroids to gain prompt control of this prolonged exacerbation. 1, 2

Why Intermittent Therapy Has Failed

This patient's clinical pattern has fundamentally changed. His historical pattern of brief, self-limited episodes responding to short-term therapy no longer applies. The persistence of symptoms beyond one month despite intermittent combination therapy indicates he now has persistent asthma requiring daily controller medication 1. The NAEPP EPR-3 guidelines explicitly state that increasing use of short-acting beta-agonists or use >2 days per week for symptom relief generally indicates inadequate asthma control and the need for initiating or intensifying anti-inflammatory therapy 1.

Immediate Management Steps

1. Add Oral Corticosteroids Now

• Prescribe 40-60 mg prednisone daily for 5-10 days 2
• No taper is necessary for courses this short 2
• This addresses the current exacerbation that has persisted for over a month
• Oral corticosteroids are specifically recommended to gain prompt control of asthma 1

2. Transition to Daily Scheduled Controller Therapy

Switch from intermittent to daily scheduled budesonide/formoterol (or equivalent ICS/LABA):

• Start with low-to-medium dose ICS/LABA twice daily (Step 3 care per NAEPP guidelines) 1, 3
• For budesonide/formoterol: 160/4.5 mcg twice daily is appropriate 4
• This represents the preferred treatment for moderate persistent asthma in adults 1, 3

Critical point: Long-acting beta-agonists (LABAs) like formoterol should NEVER be used as monotherapy—they must always be combined with inhaled corticosteroids 1. The FDA has issued a Black Box warning about this 1.

3. Provide Separate Reliever Medication

• Prescribe a short-acting beta-agonist (SABA) such as albuterol for symptom relief 1, 2
• Instruct the patient to use this as needed for acute symptoms
• Monitor SABA use: if he needs it >2 days per week (excluding pre-exercise use), this signals inadequate control requiring treatment intensification 1

Alternative Approach: SMART Regimen (If Appropriate Product Available)

If using budesonide/formoterol specifically, consider the maintenance and reliever therapy (SMART) approach 5, 6:

• Budesonide/formoterol 160/4.5 mcg twice daily as maintenance
• PLUS the same budesonide/formoterol as needed for symptom relief (replacing SABA)
• This approach reduces severe exacerbations by 21-39% compared to fixed-dose ICS/LABA plus SABA 7, 8
• Important: This only works with formoterol-containing products due to formoterol's rapid onset of action; salmeterol is too slow-acting for reliever use 5
• This is currently off-label use in the US but recommended in GINA guidelines 5

Why This Approach Works

The FACET study demonstrated that combining an inhaled corticosteroid with a long-acting beta-agonist reduced both mild and severe exacerbations by 40% and 29% respectively, even at low ICS doses 4. The key is regular daily anti-inflammatory therapy, not just bronchodilation during symptoms.

Monitoring and Follow-Up

Reassess in 2-6 weeks 1:

• Evaluate symptom control, SABA use frequency, and lung function
• If well-controlled for at least 3 months, consider stepping down therapy 1
• If inadequately controlled, step up to medium-dose ICS/LABA or consider adding a third agent (leukotriene modifier or long-acting muscarinic antagonist) 1, 3

Check adherence and inhaler technique at every visit—these are the most common reasons for treatment failure 1.

Common Pitfalls to Avoid

1. Do not continue intermittent therapy: This patient's disease pattern has changed and requires daily treatment
2. Do not use LABA without ICS: This increases risk of severe exacerbations and asthma-related death 2, 1
3. Do not simply double the ICS dose during exacerbations: Evidence shows this is ineffective 9
4. Do not forget the oral corticosteroid course: After a month of uncontrolled symptoms, he needs this to regain control 1, 2

Special Considerations for This 72-Year-Old Patient

Given his age, monitor for:

• Bone mineral density effects from long-term ICS use 10
• Glaucoma and cataracts with prolonged ICS therapy 10
• Potential drug interactions if he takes CYP3A4 inhibitors (e.g., ketoconazole) which can increase budesonide levels 10

The FDA label specifically warns about systemic corticosteroid effects and adrenal suppression, particularly at higher doses over prolonged periods 10. However, at recommended doses for asthma control, these risks are generally acceptable given the alternative of uncontrolled asthma.